BridgeBio had a very successful 2025 with a strong commercial launch of Attruby and successful phase 3 readouts of BBP-418 ...
BridgeBio Pharma (BBIO) just delivered quarterly revenue that topped expectations, powered by stronger than anticipated U.S. sales of its cardiomyopathy drug Attruby, and the stock’s reaction shows ...
BridgeBio Pharma's fair value estimate has nudged higher to roughly $84.65 per share, as analysts bake in slightly stronger revenue growth assumptions of about 80.8% driven by better than expected ...
The burgeoning field of transthyretin amyloid cardiomyopathy (ATTR-CM), which spurred excitement over a potential $20 billion market, may have just revealed the first indication of a slowdown. For the ...
Investing.com - Bernstein SocGen Group initiated coverage on BridgeBio Pharma (NASDAQ:BBIO) with an Outperform rating and a $94.00 price target on Thursday, representing nearly 30% upside from the ...
This strong performance was attributed to the robust sales of its ATTR-CM drug, Attruby, which generated $108.1 million in U.S. sales, exceeding both Goldman Sachs’ estimate of $92.3 million and ...
In other recent news, BridgeBio Pharma reported its third-quarter 2025 earnings with a revenue of $120.7 million, surpassing expectations of $107.62 million. Despite a larger-than-expected loss with ...
BridgeBio Oncology Therapeutics (BBOT) targets KRAS and PI3Ka malignancies with next-generation small molecule therapeutics, aiming to surpass current market leaders. BBOT's lead candidate, BBO-8520, ...
Hosted on MSN
BridgeBio initiated with an outperform at Bernstein
Bernstein initiated coverage of BridgeBio (BBIO) with an Outperform rating and $94 price target The firm believes expectations for Attruby are reasonable in the near-term and “arguably too high” in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback